Shots:
- Viatris has signed definitive agreements to sell its Biocon Biologics stake to Biocon for ~$815M
- Under the agreements, Viatris will sell its Biocon Biologics stake to Biocon for $400M in cash and $415M in Biocon shares, to be listed on NSE with a six-month lock-up. As part of the agreement, the biosimilar non-compete restrictions placed on Viatris in 2022 will end immediately at closing for all markets outside the US, and in Nov’26 for the US market
- The transaction is expected to close in Q1 2026, pending conditions
Ref: Viatris | Image: Viatris | Press Release
Related News: Biocon Biologics Receives Health Canada Approval for Yesintek & Yesintek IV (Biosimilar, Stelara)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
